BW Gestao de Investimentos Ltda. Invests $2.70 Million in Boston Scientific Co. (NYSE:BSX)

BW Gestao de Investimentos Ltda. bought a new stake in Boston Scientific Co. (NYSE:BSX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 30,250 shares of the medical equipment provider's stock, valued at approximately $2,702,000.

Other large investors have also added to or reduced their stakes in the company. Mechanics Bank Trust Department bought a new stake in Boston Scientific in the 4th quarter worth $415,000. Highland Capital Management LLC bought a new stake in shares of Boston Scientific in the fourth quarter worth about $4,887,000. Covenant Asset Management LLC purchased a new position in Boston Scientific during the 4th quarter valued at about $3,405,000. Brookstone Capital Management raised its position in Boston Scientific by 23.7% during the 4th quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock valued at $9,455,000 after purchasing an additional 20,307 shares during the last quarter. Finally, Beacon Investment Advisory Services Inc. lifted its holdings in Boston Scientific by 31.7% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider's stock worth $1,744,000 after buying an additional 4,702 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the transaction, the executive vice president now directly owns 25,443 shares in the company, valued at $2,704,845.33. This represents a 4.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the transaction, the executive vice president now owns 22,235 shares in the company, valued at approximately $2,269,304.10. This represents a 43.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 307,025 shares of company stock worth $31,742,060. 0.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently commented on BSX. StockNews.com upgraded Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Robert W. Baird raised their target price on shares of Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Stifel Nicolaus boosted their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Piper Sandler raised their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Finally, Needham & Company LLC upped their target price on Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, April 24th. Twenty-three equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of "Buy" and a consensus price target of $114.52.

Boston Scientific Trading Up 0.7 %

Shares of NYSE BSX traded up $0.69 during trading hours on Wednesday, hitting $104.81. 4,392,546 shares of the company traded hands, compared to its average volume of 6,342,076. The company's 50 day moving average price is $98.71 and its 200 day moving average price is $95.66. Boston Scientific Co. has a 12 month low of $71.88 and a 12 month high of $107.17. The stock has a market capitalization of $155.06 billion, a price-to-earnings ratio of 83.85, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter in the previous year, the business posted $0.56 earnings per share. The business's revenue was up 20.9% compared to the same quarter last year. On average, equities research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.